EC
NMRA icon

EntryPoint Capital’s Neumora Therapeutics NMRA Stock Holding History

EntryPoint Capital’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$216K Sell
110,875
-34,510
-24% -$89.4K 0.06% 612
2025
Q4 		$260K Buy
+145,385
New +$318K 0.1% 424
2025
Q1 		– Sell
-12,762
Closed -$135K – 863
2024
Q4 		$135K Buy
+12,762
New +$153K 0.06% 646

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

EntryPoint Capital's NMRA Position: Q1 2026 in Review

EntryPoint Capital reduced its Neumora Therapeutics (NMRA) stake by 24% in Q1 2026, selling an estimated $89.4K and leaving 110,875 shares worth $216K. The position accounts for 0.06% of the portfolio, ranked #612.

EntryPoint Capital first reported a position in NMRA in Q4 2024 and has held it in 3 quarters since. The position peaked at $260K in Q4 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • EntryPoint Capital held 110,875 shares of Neumora Therapeutics worth $216K as of Q1 2026.
  • EntryPoint Capital sold 34,510 Neumora Therapeutics shares in Q1 2026, an estimated $89.4K.
  • Neumora Therapeutics made up 0.06% of EntryPoint Capital's portfolio in Q1 2026, its #612 holding.
  • EntryPoint Capital first reported a position in Neumora Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • EntryPoint Capital's Neumora Therapeutics position peaked at $260K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.